Patent exploration with Ideation Analytics: The Paltusotine use case
Patent literature is one of the earliest available and richest sources of information in small‑molecule drug discovery — but also one of the most challenging to interpret. For medicinal chemists involved in patent exploration, competitive intelligence, and project scoping, the challenge is rarely the availability of information. Rather, it lies in efficiently gathering information, browsing hundreds of molecules, and extracting chemically meaningful insights to guide project decisions.
This article describes a use case based on the Paltusotine patent story, using Discngine’s Ideation Analytics software and its patent exploration feature. It shows how early patent analysis, supported by efficient, chemically intuitive tools, can help teams save time when exploring large and unfamiliar patent datasets to gain competitive insights.
Introduction: A first patent on somatostatin modulators with Palutostine compound
Paltusotine is the first non-peptide, selective somatostatin receptor Type 2 (SST2) agonist with a once-daily oral dosing in acromegaly patients. The drug, marketed as PALSONIFY®, was developed by Crinetics Pharmaceuticals and first approved in the United States in 2025, followed by recent approval in Europe in April 2026.
Extract from patent documentation on somatostatin modulators
One of the first international patents in which the Paltusotine compound appeared was “Somatostatin modulators and uses thereof,” published in 2018.
At the time this patent was published:
The compound’s clinical relevance was not publicly known – Palutostine (then referred to as CRN00808) was one of many molecules designed as oral somatostatin modulators
Activity data were reported only in semi-quantitative categories
The patent disclosed more than 200 compounds
From a competitor’s perspective, the situation was typical of early-stage pharmaceutical IP: a large number of compounds, broad claims, and no clear indication of which molecule the company was prioritizing. This is one of the well-suited examples for structured exploration with Ideation Analytics, performed in a retroactive manner.
Step 1: Identifying a “Good Starting Point” for patent exploration with Ideation Analytics
Imagine a medicinal chemist in the past exploring this large patent dataset with the goal of prioritizing where to start.
Using Ideation Analytics, the compounds disclosed in the patent can be accessed directly within the platform through an integration with patent databases (currently GOSTAR™). By simply entering the patent number, scientists can automatically load the full patent dataset and start analysis.
Ideation Analytics’ Patent Search bar with instant in-application access to drug patents (from GOSTAR™)
This way, patent data are accessible within a couple of minutes, without the need to frequently switch between tools or spend time on data wrangling tasks. Ideation Analytics enables rapid ranking and scoring of compounds via the Suggested Starting Point feature (see feature video here). It is based on Matched Molecular Pair (MMP) or R-Group Deconvolution (RGD) analysis and allows scientists to rank compounds or scaffolds based on their potential to provide insightful Structure-Activity Relationship information.
In this retrospective example:
The compound, later known as Paltusotine, appeared in the top 10 suggested starting points
This ranking was generated solely from the internal structure of the patent dataset
No external biological, clinical, or post‑patent information was used
N.B: It is important to clarify how this result should be interpreted. Ideation Analytics does not claim to identify “the drug candidate.” The suggested starting-point feature highlights chemically interesting compounds within a competitor’s disclosed patent space, enabling scientists to focus their exploration and form informed hypotheses about which molecules may be most relevant to analyze first.
In this case, we can call it a “happy coincidence” that the molecule that later progressed to the clinic was in position 5 in a list of over 200 compounds. This overall illustrates how the tool can surface meaningful candidates early and efficiently in the exploration process.
Ideation Analytics’ Suggested Starting Point feature: Paltusotine is shown among the top 10 compounds in the list of suggested compounds to start an MMP-based patent SAR exploration (scores in orange), demonstrating how this feature supports the initial analysis of a large, unfamiliar patent. It does not guarantee a compound's success later in trials
Step 2: Highlighting what the patent explores most with R-group deconvolution analysis
Identifying a strong starting point is only one part of the patent exploration journey. For medicinal chemists, it is equally important to understand what the patent holder explored most extensively within the disclosed chemical series.
In the Paltusotine patent dataset, this was addressed in Ideation Analytics using R‑group decomposition (RGD) analysis. Starting from the scaffold, the SAR automatic view summarizes how substituents are distributed across key positions (e.g., R1, R2, R3) and organized in colored, floating bubbles.
This representation provides another way for chemists to prioritize exploration. The SAR view shows the number of compounds in which the substituents recur most frequently, allowing scientists to drill down stepwise. For example, we first focus on the two most common R1 and R2 substituents, then examine how R3 is populated within that subset. This 2-click function instantly narrows downfrom 200+ compounds to 53 (including Paltusotine).
Ideation Analytics’ R-Group Deconvolution analysis showing substituent distribution by position. Substituents are grouped in the floating, color-colored bubbles and filtered out for easier exploration
Step 3: Rapid assessment of unexplored chemical space within the patent
Once you understand which substituents are most common at each position, the next question becomes: which combinations were actually made and disclosed — and which were not?
The Matrix view feature complements RGD analysis by presenting substituents across two positions at a time (e.g., R1 vs R2), so you can see, in the Paltusotine case, which combinations appear in the patent dataset and where cells are empty. This provides a structured view of how substituents are distributed across scaffold positions and in which combinations. Medicinal chemists can then rapidly assess which moieties and substitution patterns were most frequently explored, and which combinations were not explicitly addressed in the patent. The latter supports informed ideation around non‑obvious modifications, for example.
Ideation Analytics’ R‑group Matrix view provides an immediate visual summary of substituents and their combinations - filled cells correspond to combinations disclosed in the patent, while empty cells highlight combinations not described
What’s important to mention for this feature is that combinations that are not present in the matrix are neither obvious modifications nor automatically patentable. They simply allow chemists to indicate chemical space that a competitor did not explore in the specific patent.
Summary
Taken together, this example illustrates how Ideation Analytics supports patent exploration through efficient functionality and high-quality visualizations that follow medicinal chemists' workflows.
Using Paltusotine — a first‑in‑class oral small‑molecule treatment for acromegaly — the retrospective analysis of one of the patents in which this compound first appeared serves as a concrete example. It shows how combining starting-point prioritization with a structured visualization of the explored and unexplored chemical space enables medicinal chemists to move more efficiently from patent disclosure to actionable insight. The same workflow can be applied to any other patent exploration.
Ideation Analytics is a Discngine software for efficient Structure-Activity Relationship analysis and reporting with built-in integrations with common medicinal chemistry in-silico tools, including a patent database extension (currently Excelra GOSTAR™).
To get detailed information on the patent exploration use case and discover Ideation Analytics’ capabilities beyond those covered in this article, visit our product page and get in touch with our scientists.
Suggested read
Wondering how to overcome the challenges of analyzing compound SAR and patent data together for lead optimization? Read our blog post “Designing with novelty: why considering Structure-Activity Relationship alongside patent disclosures matters”.